Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
3.94
Change:
- 0.07
Volume:
3,260,000
4:00 PM ET on May 20, 2013
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
     

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

View all »   RSSRecent Releases

May 9, 2013
Dendreon Announces First Quarter 2013 Results

May 6, 2013
PROVENGE® (sipuleucel-T) Data Presented at An Annual Scientific Urology Meeting

Apr 24, 2013
Dendreon to Host Conference Call on May 9 to Announce First Quarter Financial Results



View all »Webcasts

May 30, 2013 at 10:40 AM ET
Deutsche Bank Securities 38th Annual dbAccess Health Care Conference

May 14, 2013 at 1:40 PM PT
Bank of America Merrill Lynch 2013 Health Care Conference



View all »Presentations

MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB

Contact

Investor Relations
206-455-2220
ir@dendreon.com

Media
206-829-1622
media@dendreon.com